{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:50:13Z","timestamp":1788306613687,"version":"build-2803163510"},"reference-count":41,"publisher":"SAGE Publications","issue":"3_suppl","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Advances in glucose monitoring technologies have led to the development of different types of continuous glucose monitoring (CGM) platforms: traditional CGM and flash CGM. Both platforms provide critical glucose data that enable persons with diabetes (PwDs) to make more informed decisions in their self-management. Until recently, a key advantage of traditional CGM over flash CGM was the availability of automatic alarms that warn users about current or impending hypoglycemia and hyperglycemia. However, with the introduction of the FreeStyle Libre 2 (FSL2) system (Abbott Diabetes Care, Alameda, CA), PwD can now utilize flash CGM with the option to set low and high glycemic thresholds and receive alarms when these thresholds are crossed. In addition, having the option to use or not use the alarms may attract previous traditional CGM users who grew fatigued by constant alarms. However, despite the additional layer of safety that alarms provide, many PwD are reluctant to switch from self-monitoring of blood glucose to CGM due to concerns about how alarms could impact the quality of their daily lives. This reluctance is heightened by their perceptions that use of alarms is mandatory. Because the functionality of the FSL2 alarms differs from current traditional CGM devices, it is important that clinicians become familiar with these differences. Moreover, clinicians will be challenged to help PwD overcome their concerns about the use of alarms. This article presents a comprehensive description of the FSL2 alarms function and provides guidance to clinicians when counseling PwDs about the strengths, limitations, and various ways that the FSL2 alarms can be used in daily diabetes self-management.<\/jats:p>","DOI":"10.1089\/dia.2021.0192","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T09:33:22Z","timestamp":1632216802000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Just Because You Can, Doesn't Mean You Should\u2009\u2026\u2009Now. A Practical Approach to Counseling Persons with Diabetes on Use of Optional CGM Alarms"],"prefix":"10.1177","volume":"23","author":[{"given":"Eden","family":"Miller","sequence":"first","affiliation":[{"name":"Diabetes Nation, Sisters, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry Kurt","family":"Midyett","sequence":"additional","affiliation":[{"name":"Midwest Pediatric Specialists, P.A., Overland Park, Kansas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31535-5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4527-5"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30217-6"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19976"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00720-0"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0255-6"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0223-6"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001092"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0166"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2855"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1610"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000809"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4894-1"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.23"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0339"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2019.07.054"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0616-4"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab013"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/ds20-0069"},{"key":"e_1_3_4_21_2","unstructured":"MEDTECHDIVE: Abbott on track to top Q4 CGM sales estimates rise in US FreeStyle Libre scripts suggests. June 15 2020. https:\/\/www.medtechdive.com\/news\/abbott-freestyle-libre-cgm-q4-prescriptions\/589539\/ (accessed March16 2021)."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0840"},{"key":"e_1_3_4_24_2","article-title":"Alarm settings of continuous glucose monitoring systems and associations to glucose outcomes in type 1 diabetes","volume":"4","author":"Lin YK","year":"2019","unstructured":"Lin YK, , Groat D, , Chan O, et al.: Alarm settings of continuous glucose monitoring systems and associations to glucose outcomes in type 1 diabetes. J Endocr Soc, 2019; 4:bvz005.","journal-title":"J Endocr Soc"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0298"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1855"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-018-0239-1"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/193229681300700324"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S24752"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/db18-724-P"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S007"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.04.008"},{"key":"e_1_3_4_33_2","unstructured":"National Institute for Health and Care Excellence: Type 1 diabetes in adults: diagnosis and management. 2015. https:\/\/wwwniceorguk\/guidance\/ng17 (Accessed February2 2018)."},{"key":"e_1_3_4_34_2","article-title":"FreeStyle Libre\u00ae System use associated with reduction in acute diabetes events and all-cause hospitalizations in patients with type 2 diabetes without bolus insulin","author":"Miller D","year":"2021","unstructured":"Miller D, , Kerr MSD, , Roberts GJ, et al.: FreeStyle Libre\u00ae System use associated with reduction in acute diabetes events and all-cause hospitalizations in patients with type 2 diabetes without bolus insulin. Am J Manag Care, 2021. [Epub ahead of print].","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0396"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1438"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816628547"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2217\/dmt.15.43"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4649303"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000320"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.2337\/db20-84-LB"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.2337\/db20-85-LB"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2021.0192","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2021.0192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:12:57Z","timestamp":1777399977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2021.0192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":41,"journal-issue":{"issue":"3_suppl","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1089\/dia.2021.0192"],"URL":"https:\/\/doi.org\/10.1089\/dia.2021.0192","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}